Kailera Therapeutics, Inc. (KLRA)

16.23 +0.49 (+3.11%) USD  |  NASDAQ  |  Sep 04, 16:00
16.24 +0.01 (+0.06%) After-Hours: 20:00
More

Kailera Therapeutics SG&A Expense (TTM) : 34.10M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for KLRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2025. Start Trial.
Date Value
June 30, 2026 34.10M
March 31, 2026 13.79M
Date Value
June 30, 2025 0.00

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Moderna, Inc. 965.00M
Revolution Medicines, Inc. 330.91M
Sana Biotechnology, Inc. 44.71M
Parabilis Medicines, Inc. 21.36M
Arrowhead Pharmaceuticals, Inc. 172.57M